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Aims: This study examined the effect of experimentally- induced hypoglycaemia on 
measures	of	myocardial	blood	flow	and	myocardial	injury	in	adults	with,	and	without,	
type 1 diabetes.
Methods: In	 a	 prospective,	 randomised,	 open-	label,	 blinded,	 endpoint	 cross-	over	
study,	17	young	adults	with	type	1	diabetes	with	no	cardiovascular	risk	factors,	and	10	
healthy	 non-	diabetic	 volunteers,	 underwent	 hyperinsulinaemic-	euglycaemic	 (blood	
glucose	 4.5–	5.5	mmol/L)	 and	 hypoglycaemic	 (2.2–	2.5	mmol/L)	 clamps.	Myocardial	
blood flow was assessed using transthoracic echocardiography Doppler coronary 





euglycaemia or hypoglycaemia as factors affecting CFR. No statistically significant 
difference in CFR was observed for diabetes status (p	=	.23)	or	between	euglycaemia	
and hypoglycaemia (p	=	.31).	No	changes	in	hs-	cTnI	occurred	during	hypoglycaemia	or	
in the recovery period (p	=	.86).
Conclusions: A	small	change	in	CFR	was	not	statistically	significant	in	this	study,	im-
plying hypoglycaemia may require more than coronary vasomotor dysfunction to 
cause harm. Further larger studies are required to investigate this putative problem.
K E Y W O R D S
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1  |  INTRODUC TION
Diabetes is now a global pandemic1 in which the principal cause of 
death is cardiovascular disease.2 While strict control improves some 
outcomes,	 clinical	 trials	 in	 people	with	 type	 2	 diabetes	who	 have	
cardiovascular disease have shown that intensive glucose- lowering 
therapy is associated with higher mortality.3,4 It has been suggested 
that exposure to hypoglycaemia may be contributing to this greater 
morbidity and mortality.5,6
Hypoglycaemia is a common occurrence in people with insulin- 
treated diabetes. It causes profound autonomic stimulation leading 
to activation of the sympatho- adrenal system with profuse catechol-
amine release. This has pronounced systemic and regional haemo-
dynamic	effects,7 including large increments in stroke volume and 
cardiac	output,8 caused by increased left ventricular ejection frac-
tion and myocardial contractility.9 This augmented cardiac workload 
may provoke myocardial ischaemia or cardiac failure in people who 
have established cardiac disease.
Mechanisms that could promote adverse effects of hypoglycae-
mia on cardiovascular function have been proposed.10 Endothelial 
dysfunction is a key pathophysiological pathway underlying macro-
vascular	complications	in	type	1	and	type	2	diabetes.	A	detrimental	
effect of hypoglycaemia on peripheral endothelial function has been 
reported.11	 However,	 several	 differences	 exist	 between	 peripheral	
and	 coronary	 arterial	 endothelium,	 such	 as	 the	 presence	 of	 shunt	
vessels and the microvascular architecture.12 Direct measurement 
of coronary vasomotor function may therefore provide a more valid 
measure of any cardiovascular impairment resulting from limited 
vascular responsiveness. Measurement of coronary microvascular 
dysfunction	by	calculation	of	coronary	flow	reserve	(CFR)	is	the	pre-
ferred investigative technique.13 Coronary flow reserve measures the 
capacity of the coronary circulation to increase flow during maximal 
resistance vessel vasodilatation. Maximal hyperaemia is achieved by 
intravenous infusion of adenosine14 and coronary flow velocity can 
be measured non- invasively by transthoracic Doppler echocardiog-
raphy.15,16 CFR is reduced in people with type 1 diabetes during eu-
glycaemia17 and in individuals with type 1 diabetes with evidence of 
microvascular disease in the form of retinopathy.18 CFR has also been 
shown to correlate well with long term hard outcomes in coronary 
heart disease.19,20 It is unclear how hypoglycaemia affects CFR.
Cardiac troponins are a biomarker of myocardial injury. In recent 
years,	the	introduction	of	a	highly	sensitive	cardiac	troponin	I	(hs-	cTnI)	
assay allows the detection of small degrees of myocardial damage. 
Lowering	the	diagnostic	threshold	for	myocardial	injury	has	improved	
outcomes for people with type 1 myocardial infarction.21 Hs- cTNI 
also provides prognostic information regarding long term outcomes in 
cohorts of people with underlying coronary heart disease.22
People	with	 type	 2	 diabetes	 often	 have	multiple	 cardiovascu-
lar risk factors that can confound attempts to investigate hypogly-
caemia as a causative mechanism for cardiovascular morbidity and 
mortality. Younger people with type 1 diabetes of relatively short 
duration are less likely to have acquired these additional risk fac-
tors. To examine whether hypoglycaemia might adversely affect 
myocardial	 blood	 flow	and	cause	myocardial	 injury,	 coronary	 flow	
reserve and cardiac troponins were therefore measured during 
experimentally- induced hypoglycaemia in people with type 1 diabe-
tes who had no confounding factors.
2  |  MATERIAL S AND METHODS
2.1  |  Study participants
Young healthy male adults with type 1 diabetes with no microvascu-
lar complications or cardiovascular risk factors were recruited from 
diabetes	out-	patient	clinics	in	Lothian,	Scotland.	Men	without	diabe-
tes,	matched	for	age,	were	recruited	by	poster	advertisements	and	
from a database of volunteers. Only male subjects were studied to 
avoid the confounding effect of the variability of coronary flow re-
serve that occurs during the menstrual cycle.23	In	addition,	because	
the counterregulatory hormonal responses to hypoglycaemia differ 
between	men	and	women,24 the study was confined to men to avoid 
a potential effect of gender on the magnitude of the sympatho- 
adrenal stimulus during hypoglycaemia.
Exclusion	criteria	 included	co-	existent	 systemic	disease,	malig-
nancy,	 chronic	 alcoholism,	psychiatric	disorder,	 any	history	of	 car-
diac	conduction	abnormality,	impaired	awareness	of	hypoglycaemia	
(as assessed by the method of Gold et al.25),	past	history	of	severe	
hypoglycaemia,	and	any	evidence	of	overt	microvascular	complica-
tions including retinopathy and neuropathy or the presence of mi-
croalbuminuria. The participants did not have any overt evidence 








consistent with average quality of glycaemic control recorded in the 
adult population with type 1 diabetes in Scotland. The two groups of 
participants	did	not	differ	in	age	or	body-	mass	index	(Table	1).	The	
participants	performed	more	frequent	glucose	testing	24	h	before	
each of the glucose clamp studies to ensure that they had not been 
exposed to antecedent hypoglycaemia before the study.
The study was conducted with the informed written consent 
of	all	subjects,	the	approval	of	the	Lothian	Medical	Research	Ethics	
committee,	and	in	accordance	with	the	Declaration	of	Helsinki.
2.2  |  Study design
Participants	attended	two	study	visits,	performed	on	separate	days	
at least 2 weeks apart to avoid any potential carry- over effects. Two 
experimental	conditions,	hypoglycaemia	(blood	glucose	2.5	mmol/L;	
99	mg/dL)	and	euglycaemia	(4.5	mmol/L;	81	mg/dL),	were	studied	in	
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a	prospective,	 randomised,	open-	label,	 blinded	endpoint,	 (PROBE)	
cross- over study. Both the group with type 1 diabetes and matched 
individuals	underwent	the	experimental	conditions,	and	then	crossed	
over. The order of the experimental method was randomised using 
alternate	randomisation	by	the	operator	of	the	glucose	clamp,	while	
the endpoint was blinded to the echocardiographer (Supplemental 
Figure	S1).	This	study	design	has	been	employed	previously	by	our	
group,26 with modifications for the cardiovascular investigations.
Participants	attended	 in	a	 fasting	state,	having	abstained	 from	
the	consumption	of	caffeine-	containing	food	and	beverages	for	24	h.	
Venous cannulae were inserted for intravenous infusion of dextrose 
and	insulin,	and	blood	sampling.	A	modified	version	of	the	hyperin-
sulinaemic glucose clamp was employed.27 To arterialise blood sam-
ples,	the	non-	dominant	arm	was	wrapped	in	a	heated	blanket	with	a	
retrograde	intravenous	cannula	inserted	into	the	forearm.	An	addi-




ples were taken at 5- min intervals and analysed by a glucose oxidase 
method	(2300	STAT;	YSI,	Yellow	Springs,	OH).	The	dextrose	infusion	
rate was adjusted to maintain the appropriate arterialised blood glu-







using a well- described technique.16,23 The timepoints were labelled 
as baseline,	 experimental (either euglycaemia or hypoglycaemia- 
blinded	to	the	sonographer),	and	recovery	(Supplemental	Figure	S1).	
Continuous electrocardiographic monitoring and regular blood pres-
sure monitoring were performed throughout the study.
2.3  |  Coronary flow velocity measurements
During	 each	 study	 condition,	 the	 left	 anterior	 descending	 coro-
nary artery was visualized by trans- thoracic echocardiogra-
phy. Transthoracic Doppler echocardiography was used for a 
non-	invasive	estimation	of	coronary	flow	velocity	(CFV),	and	maxi-
mal coronary vasodilatation was induced with an adenosine infusion 
to allow calculation of CFR. Imaging of the left anterior descend-
ing	 (LAD)	 artery	 and	measurement	 of	 coronary	 blood	 flow	 veloc-
ity	 was	 performed	 using	 a	 7.0	 MHz	 transducer	 (Acuson	 Sequoia	
512,	 Siemens	Medical	 Solutions,	 Berkshire,	UK).	 Baseline	 spectral	
Doppler signals were recorded initially in the distal portion of the 
LAD	coronary	artery	over	five	cardiac	cycles	at	end-	expiration.	To	
measure	 coronary	 flow	 reserve	 (CFR),	 intravenous	 adenosine	was	
administered	 (0.14	mg/kg/min;	 Adenocor,	 Sanofi)	 for	 up	 to	 4	min	
to record spectral Doppler signals during hyperaemic conditions.14 
Coronary velocities were measured at baseline and peak hyperaemic 
conditions from the Doppler signal recordings. Measurements were 






2.4  |  High- sensitivity cardiac troponin I 
concentration




sensitive	 troponin	 I	 assay	 (Abbott	 Laboratories).	 This	 is	 the	 first	
clinically	approved	high-	sensitivity	troponin	I	assay,	which	has	excel-
lent precision at very low concentrations. The limit of detection is 
1.2	ng/L	and	precision	profiling	in	our	laboratory	has	demonstrated	
an	 inter-	assay	coefficient	of	variation	(CV)	of	<10%	at	5	ng/L.	The	
upper	 reference	 limit	 or	 99th	 centile	 is	 16	 ng/L	 for	 women	 and	
34	ng/L	for	men.28- 30
2.5  |  Statistical methods
A	power	 calculation	was	 performed	using	 results	 from	 a	 previous	
study	using	a	similar	technique,31	a	sample	size	of	12	allows	an	80%	






Age	(years)	(median,	range) 30	(20–	35) 24.5	(21–	33) p = .13
Sex	(%	M) 100 100
Body Mass Index (kg/m2)	
(mean	±SD)







TA B L E  1 Clinical	characteristics	of	
participants with and without type 1 
diabetes
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chance	of	detecting	a	0.57	difference	 in	CFR,	which	 is	considered	
clinically relevant. The effects of hypoglycaemia on coronary flow 
reserve were assessed statistically by generalised linear mixed- 
effects	modelling,	with	the	experimental	condition	(hypoglycaemia	
and	euglycaemia)	and	diabetes	status	as	variables	affecting	CFR.	We	
have specified per subject intercepts in our mixed- effects model by 
fitting individual subjects as a random effect to account for varia-
tion in baseline values across our study population. We also added 
an interaction term for diabetes status and experimental condition 
(hypoglycaemia	or	euglycaemia)	in	our	mixed-	effects	model.
Statistical significance was taken as a two- sided p <	.05.	Unless	
specifically	stated,	results	are	mean	±	standard	deviation.	The	hsTnI	





Study participants were all healthy young men with normal a body- 
mass	 index	 (BMI).	Baseline	characteristics	of	both	groups	are	pro-
vided	 in	 Table	 1.	During	 the	 hypoglycaemia	 session	 (Table	 2),	 the	
mean	 glucose	 nadir	 was	 2.34	 ±	 0.2	 mmol/L;	 42.12	 +	 3.8	 mg/dL	
(p	<	 .001	compared	 to	baseline),	which	 is	 sufficient	 to	 stimulate	a	
brisk	 sympatho-	adrenal	 counterregulatory	 response.	 Heart	 rate,	
systolic and mean blood pressure did not change during euglycae-
mia	 in	 either	 group.	During	 hypoglycaemia,	 a	 trend	was	 apparent	
towards	an	increase	 in	heart	rate	and	systolic	blood	pressure	(BP),	
and	a	decrease	in	diastolic	BP	in	both	groups	(Table	2).	In	the	type	
1	 diabetes	 group,	 the	 increments	 in	 heart	 rate	 and	 systolic	 blood	




3.1  |  Coronary flow velocities and reserve
No differences were observed between the coronary flow veloci-
ties of the group with type 1 diabetes and the non- diabetic group 





was	 observed	 in	 young	 adults	with	 type	 1	 diabetes,	 compared	 to	
people	without	diabetes	(3.66	±	0.47	vs.	3.92	±	0.85),	but	this	did	not	
achieve	statistical	significance.	During	hypoglycaemia,	coronary	flow	
reserve trended non- significantly lower in those with type 1 diabe-
tes	than	in	the	non-	diabetic	participants	(3.54	±	0.47	vs.	3.89	±	0.89)	
(Figure	1).	From	the	generalised	linear	mixed	model	analysis,	no	sta-
tistical significance was reached for euglycaemia or hypoglycaemia 
affecting CFR (p	=	.31).	No	statistical	significance	was	noted	for	the	
effect of diabetes status on CFR (p	=	.23).	This	exploratory	model	did	
not demonstrate any significant interaction between diabetes status 
and experimental condition (p	value	=	.938).
3.2  |  High- sensitivity cardiac troponin I
The	hs-	cTnI	values	were	 in	a	skewed	distribution	and	were,	 there-
fore,	 log-	transformed	for	statistical	analysis.	No	changes	were	ob-
served in plasma high- sensitivity cardiac troponin I concentrations 
during euglycaemia or hypoglycaemia during the recovery phase in 
either	group	(Figure	2).
TA B L E  2 Plasma	glucose,	heart	rate,	systolic,	and	diastolic	blood	pressure	values	during	hypoglycaemia	and	euglycaemia	in	the	groups	of	
participants,	with	and	without	type	1	diabetes
Euglycaemic Clamp Hypoglycaemic clamp
Baseline Experimental p value Baseline Experimental p value
Glucose 
(mmol/L)





73	±	14 73	±	8 .68 66	±	12 70	±	9 .2
Systolic	BP	
(mmHg)
127	±	14 131	±	13 .58 127	±	14 130	±	9 .43
Diastolic	BP	
(mmHg)





74	±	13 76	±	10 .73 71	±	9 78	±	8 .02
Systolic	BP	
(mmHg)
124	±	15 126	±	13 .61 116	±	11 124	±	12 .001
Diastolic	BP	
(mmHg)
69	±	6 69	±	6 .52 67	±	5 64	±	5 .2
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F I G U R E  1 CFR	(scatter	and	violin	
plot)	in	participants	with	type	1	
diabetes and people without diabetes 
under euglycaemic and hypoglycaemic 
conditions. Blue represents people with 
diabetes,	and	red	for	people	with	diabetes.	
During euglycaemia the mean CFR for 
people with diabetes versus without 
was	3.66	±	0.47	versus	3.92	±	0.85,	
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4  |  DISCUSSION
The	 present	 study	 used	 a	 well-	validated,	 non-	invasive	 method	 to	




with type 1 diabetes had a trend of lower coronary flow reserve 
compared with an age- matched group of non- diabetic males. The 
modest decline in CFR was well tolerated in young men with type 1 
diabetes who were otherwise healthy and had no evidence either of 
microvascular complications or coronary heart disease; normal coro-
nary reserve was maintained.
The direct effects of hypoglycaemia on cardiac function have 
proved difficult to elucidate as insulin per se exerts direct effects on 
the heart. Fisher et al.9 showed that administration of insulin caused 
an immediate increase in left ventricular ejection fraction and pro-
voked	 sympathetic	 activation,	 both	 of	which	 occurred	 before	 any	
fall	in	blood	glucose.	As	blood	glucose	declined	progressively,	these	
responses	 became	 more	 pronounced,	 with	 the	 maximal	 changes	
coinciding with the glucose nadir.9	A	strength	of	the	present	study	
was the ability to use a non- invasive real- time assessment of cor-
onary flow reserve during acute hypoglycaemia. By using a hyper-
insulinaemic glucose clamp it was possible to compare CFR during 
euglycaemia	and	hypoglycaemia,	and	between	type	1	diabetes	and	
the non- diabetic state. The changes observed are therefore related 
to	 the	 low	blood	 glucose	 and	 counterregulatory	mechanisms,	 and	
not to the intravenous infusion of insulin per se.	Furthermore,	 this	
study provides a direct assessment of coronary vasomotor function 
which excludes other potential confounders such as hypertension or 
microvascular disease.
The main limitation of the study is the small sample size. While 
this	was	in	part	a	consequence	of	the	robust	exclusion	criteria,	the	
demanding study design also limited recruitment of potential par-
ticipants,	 specifically	because	of	 the	use	of	adenosine	 to	 induce	
maximal hyperaemia of the coronary blood vessels. The rationale 
for	using	adenosine	was	 its	 short	half-	life,	which	meant	 that	 the	
CFR values from one measurement to the next would not be con-
founded by residual effects of adenosine. The disadvantage of this 
approach is that adenosine is often poorly tolerated because it 





In	 retrospect,	 the	 power	 calculation	may	 have	 benefited	 from	
an a priori	 calculation	of	 possible	 attrition	of	 participants,	 or	 non-	
concordance	with	the	protocol.	Additionally,	 the	magnitude	of	 the	
primary	outcome	 (difference	of	0.57	 in	CFR)	may	have	been	over-	
ambitious,	 given	 that	 our	 participants	 with	 diabetes	 were	 fit	 and	
in good health. In view of the relatively small sample size of our 
study,	it	is	possible	that	we	did	not	have	sufficient	power	to	detect	
a significant interaction between diabetes status and experimental 
condition	in	the	generalised	linear	mixed	model	analysis.	Therefore,	
while this study models the direct effect of hypoglycaemia per se 
on	coronary	vasomotor	function,	the	generalisability	of	the	results	
must take into account the sample size and the exclusion of female 
participants.
A	previous	investigation	by	Rana	and	colleagues,32 which to our 
knowledge is the only other study to have explored the effect of 
acute	hypoglycaemia	on	the	myocardial	circulation,	used	sequential	
hyperinsulinaemic glucose clamps and dipyridamole- induced stress 
echocardiography to measure myocardial blood flow reserve during 
euglycaemia	 and	 acute	 hypoglycaemia	 in	 adults	 of	 both	 sexes,	 28	
with,	 and	19	without	 type	1	diabetes.32 The age range was wider 
than in the present study and included people with microvascu-
lar disease. Hypoglycaemia induced a significant fall in myocardial 
blood	flow	reserve	in	both	groups,	with	lower	values	being	observed	
in	 the	 group	with	 type	1	diabetes	 at	 all	 times	of	measurement.	A	
statistically significant association was observed with the presence 
of microvascular complications. In contrast to the present study de-
sign,	no	time	interval	was	allowed	between	the	initial	euglycaemia	
and	 the	 subsequent	 induction	 of	 hypoglycaemia,	 so	 that	 myocar-
dial blood flow reserve rose during the period of protracted eug-
lycaemia,	which	may	have	influenced	the	effect	on	the	subsequent	
hypoglycaemia.32	 In	 addition,	 the	 order	 of	 the	 euglycaemic	 and	
hypoglycaemic	clamps	was	not	randomised,	which	may	have	intro-
duced	observer	bias	and	an	order	effect.	Furthermore,	the	long	half-	
life of dipyridamole might have influenced the results. The present 
study may therefore have provided a more direct model of coronary 
flow reserve with fewer confounding factors such as the presence of 
microvascular disease and a possible residual effect of dipyridamole.
In	the	present	study,	no	significant	change	in	CFR	was	observed	
during hypoglycaemia. While a non- significant trend towards a lower 
CFR was observed in the participants with type 1 diabetes during 
euglycaemia,	 a	 trend	 towards	 a	decline	 in	CFR	was	 also	observed	
during	 hypoglycaemia,	 consistent	 with	 previous	 observations.17 
The lowest CFR values during hypoglycaemia were observed in the 
participants with type 1 diabetes. The increments in heart rate and 
systolic blood pressure in the group with type 1 diabetes did not 
achieve	statistical	significance	(Table	2),	which	was	unexpected	with	
this degree of hypoglycaemia. The small sample size may not have 
allowed sufficient sensitivity to detect small variations in pulse and 
blood	 pressure.	 An	 alternative	 interpretation	 is	 that	 some	 partici-
pants with type 1 diabetes may have had some degree of autonomic 
dysfunction or a diminished catecholamine response to hypoglycae-
mia,	which	contributed	to	the	modest	haemodynamic	changes	and	
the	lower	CFR	values	observed	in	the	group	with	type	1	diabetes.	As	




imaging has reported that myocardial blood flow reserve was 
higher at rest and lower during vasodilatory stress in people with 
type 2 diabetes compared with non- diabetic controls.33 Impaired 
myocardial blood flow reserve was associated with microvascular 
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complications	(albuminuria	and	retinopathy)	of	diabetes.	The	pres-
ent study explicitly excluded people with overt microvascular 
disease; it is possible that the development of cardiac microan-
giopathy may underlie an abnormal response to hypoglycaemia in 
type 1 diabetes.33
While no change in the highly sensitive troponin values was 
observed	during	acute	hypoglycaemia,	 this	was	measured	 in	close	
temporal proximity to the blood glucose nadir. It is possible that 
measurement in the immediate ‘recovery’ stage was made too early 
to detect a rise in plasma troponin and exclude evidence of myocar-
dial insult.
The results of the present study imply that any putative cardiac 
harm of hypoglycaemia is unlikely to be mediated solely through 
coronary vasomotor dysfunction. Other potentially harmful factors 
associated	with	 hypoglycaemia	may	 be	 required,	 such	 as	 the	 pro-
motion	of	pro-	thrombotic	mechanisms,34,35 endothelial abnormali-
ties,11 or altered cardiac electrical conduction.36,37, It should also be 
noted	that	this	study	specifically	studied	acute	hypoglycaemia,	and	
the cumulative effects of recurrent hypoglycaemia have not been 
examined.
Recent	 randomised	 controlled	 trials	 (RCTs)	 that	 did	 not	 target	
strict glycaemic control but used drugs with a low risk of hypogly-
caemia have shown beneficial cardiovascular outcomes.38,39 This is 
in	direct	contrast	 to	previous	RCTs,	 in	which	very	strict	glycaemic	
control was pursued and the incidence of severe hypoglycaemia was 
high.10 These findings suggest that avoidance of hypoglycaemia is 





with type 1 diabetes during hypoglycaemia. Further larger studies 
that include female participants are required to confirm or refute 
this observation. If the present observation of a lower CFR is con-
firmed,	this	would	raise	concern	that	hypoglycaemia	may	promote	
myocardial ischaemia in older people with diabetes who have es-
tablished coronary heart disease. While coronary blood flow should 
be examined during hypoglycaemia in people with type 2 diabetes 
who	have	a	greater	risk	of	cardiovascular	disease,	this	was	not	un-
dertaken because of the potential cardiac risk to such participants. 
The present study should be repeated in a larger number of people 
with	 type	1	diabetes,	using	a	more	 tolerable	 form	of	 investigation	
and	 a	 real	 time	biomarker	 of	 cardiac	 injury.	As	population	 studies	
have shown an association between severe hypoglycaemia and car-
diovascular risk5,40 more mechanistic studies are required to eluci-
date potential reasons for this association.
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